Treace Medical expanding onto second floor at Nocatee headquarters

The Ponte Vedra-based company already occupies the first and top levels of the four-story building.

Treace Medical Concepts’ 125,000-square-foot headquarters building in Nocatee.
Treace Medical Concepts’ 125,000-square-foot headquarters building in Nocatee.
  • Columnists
  • Mathis Report
  • Share

Ponte Vedra-based Treace Medical Concepts Inc. is expanding onto another floor at its four-story headquarters building in Nocatee.

It occupies the first and fourth floors and is building-out on the second of the 125,000-square-foot Park Place One at 100 Palmetto Place in Nocatee. 

Nocatee straddles southern Duval and northern St. Johns counties.

Tenant Contractors Inc. built-out the fourth floor for Treace at a cost of $2 million in early 2022. The city issued that permit in March 2022 for 30,260 square feet on the top floor. The first-floor build-out was approved in April 2022 at $200,000.

Treace opened that space in July 2022.

The city is reviewing a permit application for Tenant Contractors to build-out the second floor of 26,535 square feet at a cost of $2.27 million.

Connie Turner Interiors is the space designer.

Treace previously leased 23,060 square feet for its headquarters at 203 Fort Wade Road in the Fort Wade Road Office Park in Nocatee under a lease that expires in August 2026.

The company’s annual report in February 2022 said Treace entered into a 10-year triple-net lease agreement for a new 125,562-square-foot headquarters building in Ponte Vedra. 

The report said it will move into the new building in phases and occupy the full building by the second anniversary of the lease’s commencement.

John Treace

Nine years ago, John Treace set up in an office to develop plans for a medical products company.

After deciding to focus on surgical treatments for bunions and seeing a large potential market, in 2017 he moved Treace Medical Concepts Inc. and its 25 employees into a 9,000-square-foot office in the Nocatee development in Ponte Vedra.

Treace thought that was all the space his company would need for the foreseeable future.

“Fortunately, we were wrong,” Treace said July 29, 2022, as he prepared to cut the ribbon for the company’s new Nocatee headquarters building.

At that time, Treace Medical, which is marketing its bunion treatment to surgeons around the country, had about 350 employees and about 125 are moving into the four-story building at Park Place One.

The building includes office space as well as research and development and training facilities and advanced features such as 10 charging stations for employees who have electric vehicles.

VanTrust Real Estate developed Park Place One at Nocatee as part of a 675,000-square-foot Class A office park and build-to-suit opportunities.

Marc Munago, executive vice president of landlord VanTrust Real Estate LLC, said March 10 that Treace has built-out the first and fourth floors. He said work is starting on the second floor with the third to follow.

Treace Medical Concepts founder and CEO John Treace at the July 2022 ribbon-cutting of the company’s Nocatee headquarters building.

“The facility really fits our culture,” Treace said at the July 29, 2022, ribbon-cutting.

Treace founded the company after leaving his role of senior vice president at medical products company Wright Medical Group Inc. to strike out on his own.

He homed in on the treatment of bunions, a condition described on medical websites as a “bony bump” that forms on the big toe.

Consulting with surgeons led to a procedure the company calls Lapiplasty, which corrects the foot deformity and helps patients get back on their feet relatively quickly, Treace said.

The first Lapiplasty surgery was done in 2015.

Treace Medical Concepts, which completed its initial public offering in April 2021, priced a secondary offering of about 4.8 million shares Feb. 7, 2023, at $21 each.

It said net proceeds after expenses from the $100 million stock sale will be about $94 million.

Treace will use the proceeds for general corporate purposes, including research and development and sales and marketing activities.

Treace sold 11.25 million shares at $17 each in its 2021 IPO, including 6.25 million new shares and 5 million shares sold by existing stockholders.

There were no existing shares sold in the secondary offering.



Special Offer: $5 for 2 Months!

Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.